论文部分内容阅读
目的观察前列腺素E1(PGEl)对糖尿病周围神经病变患者血清谷胱甘肽过氧化物酶(GSH-Px)活性的影响,探讨其在糖尿病周围神经病变中的治疗作用。方法将60例糖尿病周围神经病变患者随机分为PGE1治疗组(PGE1组)和灯盏花素对照组(DZ组),各30例。采用周围神经病变诊断评分标准(DNS)评价两组治疗前后效果,并对两组给药前后血清GSH-Px活性进行测定比较。结果(1)PGE1组与DZ组治疗前DNS评分差异无显著性意义(P>0.05)。PGE1组治疗后DNS评分较治疗前显著下降(P<0.05)。DZ组DNS评分治疗前后改变无显著性意义(P>0.05)。两组治疗后DNS评分差异有显著性意义(P<0.05)。(2)PGE1组与DZ组用药前GSH-Px活性分别为(116.07±9.20)μg/mL、(113.00±8.87)μg/mL,治疗后分别为(138.82±9.68)μg/mL、(114.43±9.11)μg/mL。PGE1组用药前后GSH-Px活性变化差异有显著性意义(P<0.01),DZ组用药前后差异无显著性意义(P>0.05)。两组治疗后GSH-Px活性差异有显著性意义(P<0.05)。结论PGE1可以通过提高GSH-Px活性间接影响氧化平衡从而改善糖尿病周同神经细胞功能。
Objective To investigate the effect of prostaglandin E1 (PGE1) on the serum glutathione peroxidase (GSH-Px) activity in patients with diabetic peripheral neuropathy and to explore its therapeutic effect on diabetic peripheral neuropathy. Methods Sixty diabetic patients with diabetic peripheral neuropathy were randomly divided into PGE1 group (PGE1 group) and breviscapine group (DZ group), 30 cases in each group. The diagnostic value of peripheral neuropathy (DNS) was used to evaluate the effect of two groups before and after treatment, and the serum GSH-Px activity was compared before and after treatment. Results (1) There was no significant difference in DNS score between PGE1 group and DZ group before treatment (P> 0.05). The DNS score of PGE1 group was significantly lower than that before treatment (P <0.05). DZ group had no significant change of DNS score before and after treatment (P> 0.05). There was significant difference in DNS score between the two groups after treatment (P <0.05). (2) The activities of GSH-Px in PGE1 group and DZ group before treatment were (116.07 ± 9.20) μg / mL and (113.00 ± 8.87) μg / mL, respectively, and were 138.82 ± 9.68 μg / mL and 114.43 ± 9.11) μg / mL. PGE1 group before and after treatment GSH-Px activity was significantly different (P <0.01), DZ group before and after treatment was no significant difference (P> 0.05). The difference of GSH-Px activity after treatment between the two groups was significant (P <0.05). Conclusions PGE1 can improve the function of sympathetic nerve cells in diabetes mellitus by indirectly increasing the balance of GSH-Px activity.